China's "Hatch-Waxman Act" - IP Strategy for Innovative Drugs Entering China Market

OCT 8 2020

In Sep 2020, China proposed the Patent Linkage Rule (draft for comments), which will serve as the legal framework for a "Hatch-Waxman" system with Chinese characteristics, and will have a great impact on all drug developers, as well as innovative pharmaceutical companies entering the China market.

This time we invited Tony Chen, partner at Jones Day, and Chairman at Bayhelix Group, to give us a talk on the reform of China's "Hatch-Waxman Act", and IP Strategy for Innovative Drugs to Enter the China Market.

Moderator:

Invited Guests:

  • Tony Chen, Partner at Jones Day, and Chairman at Bayhelix Group

What to Expect:

  • Common patent problems for foreign biotech companies doing deals in China

  • How will China’s Proposed Patent Linkage Rules Change the Pharmaceutical IP Landscape in China

  • How to prepare your China patent portfolio to support deal-making in China

About Tony Chen:

Tony Chen is a partner at Jones Day Shanghai office and the Chairman of Bayhelix Group, a network of senior executives, investors, and professional service providers in the cross-border China life science industry. He has represented clients in complex cross-border intellectual property matters relating to China since 2004, including Abbvie, Biogen, BioMarin, Celgene, Helsinn, Hengrui, Hua Medicine, GeneScience, Sanofi, Sequoia Capital China, and Zensun.

Tony has led Jones Day's China IP team and local counsel in representing multinational pharmaceutical companies in patent invalidation and infringement disputes before China's patent reexamination board and IP courts. He has guided operating companies and investors in navigating China's myriad regulations relating to technology import and export, high and new technology enterprises, cybersecurity, foreign patent filing, and human genetic materials.

For more information, please visit here.